Straits Times Index
2,526.35+0.74(+0.03%)Nikkei
23,474.27-165.19(-0.70%)Hang Seng
24,786.13+31.71(+0.13%)
GlaxoSmithKline plc (GSK.L)
| Previous close | 1,353.60 |
| Open | 1,344.80 |
| Bid | 1,334.80 x 0 |
| Ask | 1,335.20 x 0 |
| Day's range | 1,324.40 - 1,346.00 |
| 52-week range | 1,324.40 - 1,857.00 |
| Volume | 1,551,086 |
| Avg. volume | 7,247,404 |
| Market cap | 67.002B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 10.06 |
| EPS (TTM) | 132.70 |
| Earnings date | 28 Oct 2020 |
| Forward dividend & yield | 0.76 (5.51%) |
| Ex-dividend date | 13 Aug 2020 |
| 1y target est | 1,644.50 |
- Zacks
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
GlaxoSmithKline (GSK) closed at $35.35 in the latest trading session, marking a -1.91% move from the prior day.
- Reuters
GSK to launch late-stage testing of syncytial virus vaccine
GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage trial results. RSV vaccine development has been fraught with setbacks for decades but the pharma industry is gearing up to bring a first inoculation to market over the next few years. GSK said a Phase I/II trial with about 1,000 healthy adults aged 60-80 showed that the vaccine prompted a "robust" increase in antibodies and immune cells one month after injection, indicating a stimulated immune system.
- Motley Fool
Why Surface Oncology Stock Soared Today
What happened Shares of Surface Oncology (NASDAQ: SURF) were soaring 19.1% higher as of 3:26 p.m. EDT on Monday. The big jump came after StreetInsider reported that Surface Oncology has hired an investment bank to explore selling the company, with GlaxoSmithKline (NYSE: GSK) expressing interest in acquiring the biotech.
